Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Radiotherapy | Research

Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration

Authors: Md. Shahjalal, Marufa Sultana, Jeff Gow, Mohammad Enamul Hoque, Sabuj Kanti Mistry, Ahmed Hossain, Rashidul Alam Mahumud

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Evaluating the effects of cancer diagnosis and treatment on a patient’s overall well-being is crucial and health-related quality of life (HRQoL) is a reliable metric for assessing this impact. Little is known about HRQoL among cancer survivors across various stages and treatments. The study examined individual and clinical factors influencing HRQoL among cancer survivors.

Methods

A cross-sectional study was conducted in two specialised cancer care hospitals in Dhaka, Bangladesh. Cancer-diagnosed adults receiving treatment at selected hospitals from January to May 2022 were enrolled. The 5-level EuroQol-5 Dimensions version (EQ-5D-5L) instrument was used to collect HRQoL data. HRQoL scores were derived using UK value sets. The investigation used a multivariable Tobit regression model to determine the association between independent variables and HRQoL scores.

Results

A total of 607 adult patients were enrolled, with 55% being females and 66% aged 36 to 64 years. Reported health problems in five EQ-5D domains include mobility (11%), self-care (11%), usual daily activities (19%), pain/discomfort (21%), and anxiety/depression (46%). Patients with throat, brain, lung, blood, and liver cancer had lower utility scores. Advanced-stage cancer survivors had lower utility scores (β = -49 units, 95% codfidence interval [CI]: -0.75 to -0.22) compared to early-stage survivors. Physically inactive survivors had lower utility scores by 0.41 units (95% CI: -0.51 to -0.30) compared to their counterparts. Private hospital patients had higher utility scores, whereas patients belonged to poor socioeconomic groups scored worse than wealthier ones.

Conclusions

This study highlights the impact of clinical and individual characteristics on HRQoL among cancer survivors. These findings advocate for an enhanced Bangladeshi cancer patient care model through timely interventions or programs, early detection or diagnosis, tailored treatments, and the promotion of physical activity to bolster HRQoL outcomes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
3.
go back to reference Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019 a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–44. Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019 a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–44.
5.
go back to reference Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet. 2015;385:977–1010.CrossRef Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet. 2015;385:977–1010.CrossRef
7.
go back to reference Sibeoni J, Picard C, Orri M, Labey M, Bousquet G, Verneuil L, et al. Patients’ quality of life during active cancer treatment: a qualitative study. BMC Cancer. 2018;18(1):951.CrossRefPubMedPubMedCentral Sibeoni J, Picard C, Orri M, Labey M, Bousquet G, Verneuil L, et al. Patients’ quality of life during active cancer treatment: a qualitative study. BMC Cancer. 2018;18(1):951.CrossRefPubMedPubMedCentral
8.
go back to reference Schulte FSM, Chalifour K, Eaton G, Garland SN. Quality of life among survivors of adolescent and young adult cancer in Canada: a Young Adults With Cancer in Their Prime (YACPRIME) study. Cancer. 2021;127:1325–33.CrossRefPubMed Schulte FSM, Chalifour K, Eaton G, Garland SN. Quality of life among survivors of adolescent and young adult cancer in Canada: a Young Adults With Cancer in Their Prime (YACPRIME) study. Cancer. 2021;127:1325–33.CrossRefPubMed
9.
go back to reference Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, et al. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:969–77.CrossRefPubMedPubMedCentral Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, et al. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:969–77.CrossRefPubMedPubMedCentral
10.
go back to reference Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, et al. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes. 2019;17(1):11.CrossRefPubMedPubMedCentral Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, et al. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. Health Qual Life Outcomes. 2019;17(1):11.CrossRefPubMedPubMedCentral
11.
go back to reference Voon PJ, Cella D, Hansen AR. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer. 2021;127:1360–8.CrossRefPubMed Voon PJ, Cella D, Hansen AR. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer. 2021;127:1360–8.CrossRefPubMed
12.
go back to reference de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–26.CrossRefPubMed de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–26.CrossRefPubMed
13.
go back to reference Ganz PA, Hays RD, Spritzer KL, Rogatko A, Ko CY, Colangelo LH, et al. Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R-04. Cancer. 2022;128:3233–42.CrossRefPubMed Ganz PA, Hays RD, Spritzer KL, Rogatko A, Ko CY, Colangelo LH, et al. Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R-04. Cancer. 2022;128:3233–42.CrossRefPubMed
14.
go back to reference Buiting HM, Olthuis G. Importance of quality-of-life measurement throughout the disease course. JAMA Netw Open. 2020;3:e200388. Buiting HM, Olthuis G. Importance of quality-of-life measurement throughout the disease course. JAMA Netw Open. 2020;3:e200388.
15.
go back to reference Zheng S, He A, Yu Y, Jiang L, Liang J, Wang P. Research trends and hotspots of health-related quality of life: a bibliometric analysis from 2000 to 2019. Health Qual Life Outcomes. 2021;19:5–8.CrossRef Zheng S, He A, Yu Y, Jiang L, Liang J, Wang P. Research trends and hotspots of health-related quality of life: a bibliometric analysis from 2000 to 2019. Health Qual Life Outcomes. 2021;19:5–8.CrossRef
16.
go back to reference Zapatero A, Pijoan XM, Gómez-Caamaño A, Masferrer JP, Hernández VM, Morón AH, et al. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the expanded prostate cancer index composite for clinical practice in Spain. Health Qual Life Outcomes. 2021;19:4–6.CrossRef Zapatero A, Pijoan XM, Gómez-Caamaño A, Masferrer JP, Hernández VM, Morón AH, et al. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the expanded prostate cancer index composite for clinical practice in Spain. Health Qual Life Outcomes. 2021;19:4–6.CrossRef
17.
go back to reference Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, et al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017;15(1):130.CrossRefPubMedPubMedCentral Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, et al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017;15(1):130.CrossRefPubMedPubMedCentral
18.
go back to reference Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, NíDhochartaigh S, et al. Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health Qual Life Outcomes. 2020;18(1):353.CrossRefPubMedPubMedCentral Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, NíDhochartaigh S, et al. Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health Qual Life Outcomes. 2020;18(1):353.CrossRefPubMedPubMedCentral
19.
go back to reference Su M, Yao N, Shang M, Shen Y, Qin T, Wang J, et al. Frailty and its association with health-related quality of life among older cancer patients: an evidence-based study from China. Health Qual Life Outcomes. 2022;20(1):124.CrossRefPubMedPubMedCentral Su M, Yao N, Shang M, Shen Y, Qin T, Wang J, et al. Frailty and its association with health-related quality of life among older cancer patients: an evidence-based study from China. Health Qual Life Outcomes. 2022;20(1):124.CrossRefPubMedPubMedCentral
20.
go back to reference Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38:769–77. Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38:769–77.
21.
go back to reference Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics. 2020;38:575–91. Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics. 2020;38:575–91.
23.
go back to reference Alam MM, Rahman T, Afroz Z, Chakraborty PA, Wahab A, Zaman S, et al. Quality of life (QoL) of cancer patients and its association with nutritional and performance status: a pilot study. Heliyon. 2020;6:e05250. Alam MM, Rahman T, Afroz Z, Chakraborty PA, Wahab A, Zaman S, et al. Quality of life (QoL) of cancer patients and its association with nutritional and performance status: a pilot study. Heliyon. 2020;6:e05250.
25.
go back to reference Gao F, Ng GY, Cheung YB, Thumboo J, Pang G, Koo WH, et al. The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J Clin Epidemiol. 2009;62:206–13.CrossRefPubMed Gao F, Ng GY, Cheung YB, Thumboo J, Pang G, Koo WH, et al. The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J Clin Epidemiol. 2009;62:206–13.CrossRefPubMed
26.
go back to reference Kenzik KM, Martin MY, Fouad MN, Pisu M. Health-related quality of life in lung cancer survivors: latent class and latent transition analysis. Cancer. 2015;121:1520–8. Kenzik KM, Martin MY, Fouad MN, Pisu M. Health-related quality of life in lung cancer survivors: latent class and latent transition analysis. Cancer. 2015;121:1520–8.
27.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral
28.
go back to reference Pan T, Mulhern B, Viney R, Norman R, Hanmer J, Devlin N. A comparison of PROPr and EQ-5D-5L value sets. Pharmacoeconomics. 2022;40:297–307.CrossRefPubMed Pan T, Mulhern B, Viney R, Norman R, Hanmer J, Devlin N. A comparison of PROPr and EQ-5D-5L value sets. Pharmacoeconomics. 2022;40:297–307.CrossRefPubMed
29.
go back to reference Gabrio A, Mason AJ, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations. PharmacoEconomics - Open. 2017;1:79–97. Gabrio A, Mason AJ, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations. PharmacoEconomics - Open. 2017;1:79–97.
30.
go back to reference Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294–303.CrossRefPubMed Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294–303.CrossRefPubMed
31.
go back to reference Liao KC, Chuang HC, Chien CY, Lin YT, Tsai MH, Su YY, et al. Quality of life as a mediator between cancer stage and long-term mortality in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy. Cancers (Basel). 2021;13(20):5063.CrossRefPubMed Liao KC, Chuang HC, Chien CY, Lin YT, Tsai MH, Su YY, et al. Quality of life as a mediator between cancer stage and long-term mortality in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy. Cancers (Basel). 2021;13(20):5063.CrossRefPubMed
32.
go back to reference Ayalew TL, Wale BG, Haile KE, Zewudie BT, Feleke MG. Health-related quality of life and associated factors among cancer patients in Ethiopia: Systematic review and meta-analysis. PLoS ONE. 2022;17:e0277839.CrossRef Ayalew TL, Wale BG, Haile KE, Zewudie BT, Feleke MG. Health-related quality of life and associated factors among cancer patients in Ethiopia: Systematic review and meta-analysis. PLoS ONE. 2022;17:e0277839.CrossRef
33.
go back to reference Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B. Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep. 2021;4:e1312. Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B. Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep. 2021;4:e1312.
34.
go back to reference Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14:1–10.CrossRef Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14:1–10.CrossRef
35.
go back to reference Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014;10:332–8.CrossRefPubMed Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014;10:332–8.CrossRefPubMed
36.
go back to reference Patel VR, Hussaini SMQ, Blaes AH, Morgans AK, Haynes AB, Adamson AS, et al. Trends in the prevalence of functional limitations among US cancer survivors, 1999–2018. JAMA Oncol. 2023;9(7):1001–3.CrossRefPubMed Patel VR, Hussaini SMQ, Blaes AH, Morgans AK, Haynes AB, Adamson AS, et al. Trends in the prevalence of functional limitations among US cancer survivors, 1999–2018. JAMA Oncol. 2023;9(7):1001–3.CrossRefPubMed
37.
go back to reference Ryu M, Hwang JI. Cancer site differences in the health-related quality of life of Korean cancer survivors: results from a population-based survey. Public Health Nurs. 2019;36:144–54.CrossRefPubMed Ryu M, Hwang JI. Cancer site differences in the health-related quality of life of Korean cancer survivors: results from a population-based survey. Public Health Nurs. 2019;36:144–54.CrossRefPubMed
38.
go back to reference Malik M, Rizwan I, Hussain A. Health related quality of life among blood cancer patients in Pakistan: a cross sectional survey. Inquiry. 2021;58:004695802110252.CrossRef Malik M, Rizwan I, Hussain A. Health related quality of life among blood cancer patients in Pakistan: a cross sectional survey. Inquiry. 2021;58:004695802110252.CrossRef
39.
go back to reference Rahman T, Gasbarro D, Alam K. Financial risk protection against noncommunicable diseases: trends and patterns in Bangladesh. BMC Public Health. 2022;22(1):1835.CrossRefPubMedPubMedCentral Rahman T, Gasbarro D, Alam K. Financial risk protection against noncommunicable diseases: trends and patterns in Bangladesh. BMC Public Health. 2022;22(1):1835.CrossRefPubMedPubMedCentral
40.
go back to reference Ansar A, Lewis V, McDonald CF, Liu C, Rahman MA. Factors influencing the timeliness of care for patients with lung cancer in Bangladesh. BMC Health Serv Res. 2023;23(1):261.CrossRefPubMedPubMedCentral Ansar A, Lewis V, McDonald CF, Liu C, Rahman MA. Factors influencing the timeliness of care for patients with lung cancer in Bangladesh. BMC Health Serv Res. 2023;23(1):261.CrossRefPubMedPubMedCentral
Metadata
Title
Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration
Authors
Md. Shahjalal
Marufa Sultana
Jeff Gow
Mohammad Enamul Hoque
Sabuj Kanti Mistry
Ahmed Hossain
Rashidul Alam Mahumud
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11670-z

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine